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INTRODUCTION 
Medication reviews are intended to improve the quality, safety and appropriate use of medicines 1.  
There is an extensive international literature to demonstrate the effectiveness of pharmacist 
delivered medication reviews.   For example, reduced health problems, increased medication 
adherence and quality of life are reported consistently in systematic reviews 2, 3.  Interpreting the 
findings of these reviews in relation to the specific context of UK community pharmacy is 
challenging.  Differences in terminology and service configurations across countries are apparent, 
and meta-analyses often include pharmacist interventions from a mix of clinical settings and do not 
present effect sizes for community pharmacies alone2, 3.  There is also a large degree of 
heterogeneity in intervention content and delivery models within and across countries 3, including 
Medicines Therapy Management services in the US4 and Home Medication Review in Australia5 
which have similarities to UK pharmacy-led medicines review services.   
Since 2005 all community pharmacists in the UK are contracted by the NHS to deliver essential 
services (such as dispensing).  A second tier of ‘advanced’ contracted services includes Medicines 
Use Reviews (MURs) and the New Medicine Service (NMS), requiring community pharmacists who 
chose to deliver them to be appropriately trained and to meet specified service requirements6; these 
services are free to patients.  Remuneration for contracted pharmacies from the NHS is £28 per 
MUR, up to a maximum of 400 per year, and up to £28 per NMS depending on numbers completed7.  
The purposes of MURs are to improve patients’ understanding of their medicines and adherence, 
particularly among those with chronic conditions, highlight problematic side effects and propose 
solutions where appropriate, and to reduce medicines wastage 8.  The NMS supports people with 
long-term conditions and newly prescribed medication improve their medicines adherence, and 
there is also an explicit aim for the NMS to support patients make decisions about their treatment 
and self-management 9.    Most trials and other evaluation studies typically examine medication 
reviews for specific health conditions.  Studies of medication reviews, of the types delivered by UK 
community pharmacists, which could include medicines for a range of conditions, are much less 
common.  Thus, in one review, only five studies (4 RCTs and 1 prospective cohort study) were 
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classified as MUR type adherence reviews delivered in a pharmacy, and most interventions included 
were disease specific 3.   
Extending the community pharmacist role in the UK beyond traditional dispensing is valued as an 
opportunity to demonstrate the worth, and further develop the skills, of the profession 10.  Among 
patients, the range of pharmacists’ skills and training can be under-appreciated, to the extent that 
this can be a barrier to discussion of health behaviours 11.  Some qualitative studies report that 
patients’ perceptions of pharmacists as appropriately skilled to provide medicines related 
information and care are influenced positively by having already experienced medication reviews 10.  
Much hinges on individual pharmacist’s communication and interpersonal skills, which are noted to 
be a source of variability in the conduct of medication reviews 10.  It is, therefore, not surprising that 
skills in behaviour change and communication strategies are identified as training needs 10, 12, 
particularly for longer qualified pharmacists whose training predates attempts to increase attention 
to these elements 12. 
Community pharmacies offer a range of public health services, including sexual health screening, 
smoking cessation and alcohol interventions 13.  Delivery of these services during the course of 
routine NHS contacts is encouraged 14 and community pharmacies are well placed to provide them 
15; current MUR/NMS service specifications require pharmacists to ask patients about these and 
document any advice given.  A systematic review of community pharmacist views found broad 
support for an increased public health role, but training needs and lack of confidence in how to 
intervene to support health behaviour change were also reported16.  Medication reviews provide 
valuable opportunities to discuss with patients the possible consequences of specific behaviours for 
the effectiveness of medications, and for their health more generally.  Potentially, this could be 
more comprehensive, and use more sophisticated methods, than the ‘advice giving’ associated with 
dispensing related interactions with patients17. This is congruent with General Pharmaceutical 
Council practice standards that place the interests and perspectives of the patient at the heart of 
patient consultations 18.  Informed by the Medication Related Consultation Framework (MRCF)19, 
these standards detail how pharmacists can use core skills to make their consultations about 
medications more patient-centred.  The expectation is that all pharmacists are working towards, or 
have achieved, the required consultation skills which underpin these standards 20.   
 
This aim of this scoping review was to identify and examine existing empirical evidence in peer-
reviewed journals relating to MUR and NMS consultations delivered by community pharmacists in 
the UK.  Objectives were to: (1) identify and summarise the findings of existing  MUR and NMS 
studies; (2) examine key features of these services, including barriers and facilitators to 
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implementation (3) identify limitations and gaps in this literature; (4) identify any policy and practice 
implications based on existing findings. 
 
METHOD 
We used systematic searches to identify and map all of the available MUR and NMS empirical 
literature in a scoping review.  Within this mapping exercise, we sought data on the conduct of MUR 
and NMS consultations, the perceptions of pharmacists and patients, and the outcomes of 
consultations.   
Inclusion and exclusion criteria 
Searches of primary research studies published in journal articles between 2005 (when MURs were 
introduced; the NMS was introduced in 2011) and  May 2018 were conducted in MEDLINE, PycINFO, 
Embase and Scopus databases, selected to achieve broad coverage of the review topic.  Searches 
were limited to empirical studies with at least some data specific to these services.  Reviews, articles 
with no primary data, and studies of similar non-UK services were excluded.  No restrictions on study 
design were applied. 
Search strategy 
Search terms for each database were ‘medicine* use review’, ‘MUR’, ‘new medicine service’ and 
‘NMS’.  Titles and abstracts of papers for potential inclusion were screened independently by two 
co-authors (DS & LN).    Disagreements or uncertainties about specific papers were resolved by 
discussion with a third co-author (JM).  Reference lists of identified articles relevant to the review 
but rejected because of exclusion criteria, and reference lists of included articles, were manually 
searched for additional eligible studies.   
 
Extraction and analysis 
An Excel data extraction form was used to record year of publication,  type of services delivered, 
study objectives, design and methodology, sample type and size, data collection time frame, and key 
study quantitative and/or qualitative findings. Systematic mapping of extracted data against these 
headings was conducted by one co-author (DS), and the content checked by the other co-authors.  A 
narrative synthesis was undertaken to meet the study objectives.  As a scoping review, the quality of 
studies was not evaluated formally. 
 
RESULTS 
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A total of 461 articles were identified through database searching, and an additional 6 from hand 
searches (Figure 1).  After removal of duplicates, 141 titles and abstracts were screened, from which 
46 full text papers were assessed for eligibility.  Five studies were excluded: no empirical data (n=3); 
not MUR/NMS (n=1); a study of recruitment difficulties to a feasibility study already included in this 
review (n=1).  Of the 41 papers included in the review, 28 were of MURs, 10 of NMS and 3 for both 
services.        
The characteristics of the 41 MUR and NMS papers are described in Tables 1-5.  Few studies 
employed an RCT or quasi-experimental design: one study (two papers examining effectiveness and 
cost-effectiveness) was an RCT 21, 22, one was a small (randomised) feasibility study 23, and another 
recruited a non-randomised control group 24.  Three papers exclusively examined secondary data 
from pharmacy records 25-27.  A further five mixed methods studies used secondary data in 
combination with other (mainly qualitative) data collection 28-32.  The remainder of papers were from 
qualitative studies (n=14), including four papers from the same study 17, 33-35, and from surveys 
(n=15). 
Barriers and facilitators to implementation 
A number of studies concluded that health system factors contribute to variable levels of integration 
of MURs into routine patient care.  In particular, studies using observation of consultations, 
interviews and surveys identified lack of communication and collaboration between community 
pharmacists and GPs 29, 33, 36 as a barrier to implementation and thus limiting the potential benefit to 
patients.  Similarly, poorly developed relationships with GPs identified though observation and 
interviews 37, 38 and perceived lack of interest and awareness (from interviews and focus groups) by 
GPs 39, 40 have been reported to impede implementation of the (more recent) NMS.    
The organisational setting of the pharmacy is an important factor facilitating the uptake of MURs, 
with experiences differing by pharmacy type.  There is evidence for contrasting approaches to 
enhanced services in multiples and independents 25, 28, 29, 41, confirmed by analysis of national MUR 
data showing more extensive adoption in the former 30, perhaps driven by internal company 
pressures to achieve MUR targets 42.  A retrospective study of pharmacy records found significantly 
more patients per pharmacy were seen for targeted respiratory MURs in Healthy Living Pharmacies 
31.  The numbers of MURs performed by pharmacists varies 32 and appears to be affected by the 
pharmacists' working hours and whether store based rather than locum pharmacists 43.  Availability 
of a consultation area suitable for performing MURs and pharmacists having sufficient time available 
to perform them are also identified as influencing the number of MURs conducted43.   
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Some patient groups have more limited access to medication consultations, including the elderly 44, 
and one survey found limited uptake in a rural community45 .Perceived difficulties taking consent 
have been cited by pharmacists as the main reason for not undertaking MURs or the NMS with 
young people and/or their carers 46. More generally, one study reported that pharmacists avoid 
more complex cases (for example, with multiple conditions) because they were judged to be more 
difficult to recruit and would take more time to complete 33.  Patients from marginalised 
communities (e.g. people with disabilities, diagnosed with a serious mental illness, or with no fixed 
abode) are not always aware of enhanced pharmacy services but would welcome greater 
engagement, while pharmacists find it more difficult to identify, communicate with and 
accommodate the specific needs of these patients within the context of the busy pharmacy 
environment 47.  
Patient perceptions 
Patients' perceptions of MURs and NMS are broadly positive 34, 48.  A survey of over 500 patients 
following an MUR (although the response rate was very low; 24%) found high levels of patient 
satisfaction with the service across a number of domains, even if some patients were initially 
reluctant to take part in a MUR 49.  Patients have reported learning more about their medicines and 
side effects after a MUR, and to have improved their compliance 32, 50. More detailed examination of 
patient experiences using observation of MURs and patient interviews indicated that although 
patients appreciate the opportunity to discuss medication with a pharmacist, MUR consultations do 
not necessarily improve their knowledge of medicines or affect how they used them 34.  Patients 
have been found to value the two way dialogue with pharmacists and be able to ask questions51.  
Misalignment between patients’ and pharmacists’ framing of the purpose and potential benefits of 
the NMS has also been reported 52, as well as variations in the information available to patients 
about the nature of pharmacist-patient roles53.  More general expectations of these services among 
pharmacists and the public have been found to be similarly high to each other 48.     
Pharmacist perceptions 
Overall, community pharmacists are positive about the idea of MUR and NMS services, and view 
them as an opportunity to use their skills.  Studies report community pharmacists’ confidence to 
undertake MURs to be high 41, 54 and perceive the service to be of value to patients 43.  Pharmacists 
appear to underestimate the willingness of patients compared to the general public to engage with 
enhanced pharmacy services 48.  One small survey found opinions differed as to whether MURs 
constitute a tick-box exercise 55, but found agreement that MURs should strike a balance between 
clinical (e.g. ensuring patients take correct medication) and behavioural (e.g. using medication in the 
correct way) content. 
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Despite pharmacists holding positive views about the potential value of the NMS 40, reflections on 
practice suggest they are not convinced of its necessity for some patients.  Qualitative evidence 
indicated that many consultations did not identify any problems with the patients' medicines, raising 
questions about targeting 37. Thus, focus groups with community pharmacists have identified 
potential benefits of the NMS service, but opinions of implementing the NMS in practice are much 
more mixed 38. Prior to the introduction of the NMS, payment structure, speed of implementation, 
and the availability of supporting materials were cited by pharmacists as potential barriers to 
implementation 40.  The influence of these or other environmental factors on practice has not been 
examined in more recent literature. 
Conduct of consultations 
The duration of these consultations is short.  A survey of 341 pharmacists estimated MUR 
consultations to take an average of 10 minutes and the NMS an average of 12 minutes, durations 
which were found to be acceptable to both pharmacists and patients 48.  Ethnographic observations 
of 54 MUR consultations and interviews with 34 MUR patients and 5 pharmacists 17 had a number of 
key findings.  MUR consultations were brief and involved mainly closed questions to enable quick 
and easy completion of the MUR form; the MUR was often introduced as a quick check of medicines.  
Opportunities for patients to ask questions were minimised.  Pharmacists were reluctant to engage 
in discussion of patients’ illnesses, which patients often raised.  Thus, the consultations did not 
address how patients might manage their illness better with their medicines, and had little impact 
on medicine use.  From this study, it is doubtful that the depth of engagement with patients and 
their health problems during consultations is sufficient to fulfil the purposes of MURs beyond 
checking safety.  Pragmatic constraints of workload and pharmacy organisation were reported by 
pharmacists as barriers to effective MUR implementation.   
In contrast, one small observational study of MUR consultations (n=7) reported that patients valued 
discussion with the pharmacist, when it involved an exchange of information rather than simply 
information giving 56.  Similarly, standardised documentation for MURs may not constrain 
pharmacists’ autonomy to adapt the material, to avoid a formulaic approach to medication 
discussions 42. MUR quality indicators have been proposed to improve recording of consultations 
having been delivered 57.  
Concern has been expressed that opportunities for NMS consultations are more limited than 
originally intended 26.  This is supported by a pharmacist survey that found low levels of NMS 
provision for patients prescribed oral anti-coagulants for stroke prevention in atrial fibrillation 58.  
Observations and interviews with patients suggest NMS consultations to be a pharmacist led 
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questioning of the patient, with variation in the extent to which pharmacists keep to a formal NMS 
discussion schedule 52.  Focus groups with pharmacists before NMS implementation identified 
interview techniques and communication skills as being important for the successful delivery of NMS 
but not something requiring further training 40.  Pharmacists also had positive attitudes to providing 
the service, seeing it as an opportunity to use their clinical skills to benefit patients.  In practice, the 
importance of pharmacists’ communication and interpersonal skills is underlined by the pragmatic 
approaches taken to implementing medication reviews.  An observational study of NMS delivery 
reported pharmacists using strategies to persuade patients to have NMS and attempting to keep an 
informal tone to discussions 37. The NMS question guide was thus adapted to suit conversation flow 
and pharmacists’ perceptions of the purpose of NMS.  Whilst some managed patient discussions 
competently, this study also found evidence that pharmacists needed to enhance their consultation 
and communication skills to ensure that NMS consultations are patient-centred. For example, some 
regarded NMS to be information giving, rather than exploring patient understanding of medication, 
calling into question how patient-centred the service delivered can be expected to be.  Using a 
similar methodology Waring et al. reported that not all pharmacists were equally skilled at 
communicating with their patients during NMS consultations, with some more able to go ‘off-script’ 
to ask about lifestyle factors 59.  Significantly, these pharmacists tended to more experienced and 
concerned with developing a relationship with patients.     
Very little information is available in the literature on the extent of discussion or advice on health 
behaviours during consultations.  A pharmacist completed survey reported over a fifth of NMS 
patients received advice on such issues, most commonly on diet, with alcohol and smoking advice 
provided to around 40% of these patients 60.  Such shortcomings extend beyond the conduct of 
MURs and the NMS, indicating broader challenges to moving from a traditional community 
pharmacist role to consistent adoption of patient-centred approaches to practice. Interviews with 15 
community pharmacists suggested a perception that cardiovascular disease patients may react 
negatively to the uninvited offer of health behaviour advice, and in turn made pharmacists reluctant 
to discuss broader issues of relevance to patients’ health 61. Some pharmacists in the sample felt that 
they did not receive appropriate skills training to offer patients such advice, although confidence to 
do this appeared to develop over time.  Management of long term conditions has been described by 
pharmacists as identifying medication issues and informing/educating patients about it, rather than 
actively involving patients in decision making about their medication 62.  A more recent focus group 
and interview study 63 with a range of pharmacists and staff, including 6 early career community 
pharmacists and 8 community pharmacy pre-registration tutors reinforced the need to avoid 
technical language during consultations, avoiding being overly friendly (pharmacists perceived this to 
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be off-putting to patients) and flexibility to adapt communication style to individual patients.  Thus, 
overly formalised interventions cannot facilitate patient centred care. 
Outcomes 
The majority of studies were qualitative or surveys and typically of small scale, and few studies 
evaluated outcomes of MURs or the NMS in any way.  To date only one randomised trial (of NMS) 
has been conducted.  This trial recruited 504 participants, allocated to NMS or usual care, and 
measured self-reported medication adherence at 10 weeks follow-up, defined as missing no doses 
without the advice of a medical professional in the previous 7 days 21.  NMS significantly increased 
the proportion of patients adhering to their new medicine by about 10%, and was significant in 
intention to treat analyses and after adjustment for missing data.   Economic modelling of adherence 
outcomes, using NHS and non-NHS resource use costs and costs of the intervention costs, found 
health benefit at lower cost attributable to NMS; a mean of 0.05 more QALYs per patient, at a mean 
reduced cost of -£144 22.  Although this was designed as a pragmatic trial, it is unclear how far these 
findings may generalise to the outcomes that may be expected when NMS is delivered in routine 
practice. 
A range of outcomes have been reported by studies not robustly designed to identify outcomes.  A 
quasi-experimental study of post-hospital counselling and community pharmacist MURs improved 
patients’ knowledge of their medication, but was undermined by less than half of patients for whom 
a MUR was recommended actually receiving one 24;  the primary reason was patients having their 
medicine delivered to their home, and thus not requiring a visit to a community pharmacy.  Lack of 
mobility has also been identified as a barrier to conducting post-hospital discharge MURs in a small 
feasibility trial 23.  In a large survey-based evaluation of hospital referrals to a community pharmacy 
follow-up service, MUR (n=288) or NMS (n=241) consultations were the most common types of 
service provided (if provided at all), with results indicating that patients receiving a follow-up 
consultation (of any type) may have lower rates of readmission and shorter hospital stays 27.  A 
patient survey (n=232, from 4 community pharmacies) found that those who had received an 
advanced pharmacy service, such as a MUR, reported greater medicines adherence and satisfaction 
with medicine related information 64.  There may be unintended consequences to pharmacists 
spending time undertaking these consultations: support-staff report feeling frustrated when left to 
explain to patients that the pharmacist is not available because they are conducting an MUR 35.    
DISCUSSION 
The MUR and NMS literature largely focuses on the introduction and early implementation of these 
services, with little detailed attention to process and outcomes for patients.  The international 
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literature of pharmacist- led medication reviews convincingly shows improved disease-specific and 
medication adherence outcomes 2, but beyond the single NMS RCT 21 the effectiveness of UK 
medication related advanced services has not been evaluated, despite on-going challenges to 
successful implementation65.  Confidence that the specific aims of MUR and NMS consultations 8, 9 
will be achieved in practice is, therefore, limited by the research evidence available.    
There is enthusiasm for MURs and the NMS from both pharmacists and patients as a means to 
improve the way medication is taken, and by implication effectiveness and safety 34, 38, 41, 43, 48-50, 55.  In 
practice, discussions of medicines appear to often involve one-way communication of information 
from pharmacists to patients 17, 37, 52, described previously as an ‘educator/informer’ role 10, with 
limited exploration of patient perspectives or attempt to gain the broader understanding of patient 
circumstances 17, 33, 34, 59 that should be expected to provide secure foundations for consultation 
practice 18.  There is scant information in the literature about how community pharmacists perceive 
implementation of these services to have changed or developed their practice, or how they may 
benefit patients.  Similarly, very little is known about patients’ perspectives of whether and how 
medicine consultations influence their own behaviour.  These are essential elements to better 
understanding mechanisms that underpin delivery and outcomes of medication reviews, and could 
usefully inform future advances in UK community pharmacy practice.   
Development and roll-out of consultations skills training for pharmacists 66 occurred in 2014, after 
the introduction of MURs and the NMS.  In such circumstances it might be expected that the 
conduct of the services reported in earlier studies does not reflect practice standards aspirations.  
Pharmacists’ skills in behaviour change and in communication have been identified as training needs 
10, 12, particularly for longer qualified pharmacists whose training predates attempts to increase 
attention to these elements 12.  Turning person-centred rhetoric into tangible experiences of the 
delivery of medication reviews involves supporting pharmacists to engage with patients as active 
participants in decision making and ensuring that any information and advice offered is meaningful 
and appropriate to their needs 67, 68.  Future initiatives will also need to account for external factors 
that influence what happens in consultations, beyond the control of individual community 
pharmacists, including the organisational cultures of different types of pharmacy, funding structures 
and targets, constraints on pharmacists’ time and relationships with GPs.  Secondary analysis of data 
published after the searches for this review were completed shows that implementation of the NMS 
can be achieved with minimal impact on GP services 69. 
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Examples of more person-centred practice can be found in the literature 37, 42, 55, 56, 59 and include: (a) 
avoiding using consultations as a medicine checking exercise; (b) adopting a flexible and informal 
communication style; (c) asking open questions; (d) exploring issues relevant to patients’ 
condition(s); (e) checking patient understanding of issues raised in consultations; (f) using 
consultations to build relationships.  Some pharmacists are skilled at adapting the standardised 
discussion schedules to the individual circumstances of the patient 37, 42.  Greater experience may be 
a factor 59, but the reasons for such varied practice and identification of mechanisms to improve it 
require further research and elaboration.   
Pharmacists typically view addressing patient’s broader health as important and a legitimate part of 
their role, but secondary to medicine related issues 16.   A range of barriers to pharmacists raising 
and discussing lifestyle factors have been identified by previous international reviews, including lack 
of time, low confidence, insufficient skills, lack of demand, and perceptions among pharmacists that 
patients may react negatively to unwanted advice 16, 70.  Thus attention to medication use 
unsurprisingly lies at the heart of medicines consultations.  Recognising the public health potential of 
community pharmacies, the Healthy Living Pharmacy framework, encompassing workforce 
development, improving premises and community engagement, was introduced to foster health 
promotion activities after successful piloting 31.  The impact of this initiative on the delivery of 
medication consultations, and on the barriers to person-centred practice identified above, has yet to 
be examined.  Evidence from this review indicates that attention to health behaviours is often not 
included in medication consultations, or is considered incidental to the primary purposes of the 
service provision.   
Improving the quality of life and care for the rising numbers of people with long term conditions is a 
UK policy priority 14, 71, 72.  This presents opportunities for pharmacists to play a major role in 
improving the health and wellbeing of this population, including optimising the contributions of 
routine pharmacy services such as medication reviews.    There is untapped potential in utilising 
existing medication review consultations to address patient agendas in the manner proposed by the 
policy documents and in the training materials developed for community pharmacists. 
There are some limitations to this review.  Although we aimed to map the existing MUR and NMS 
literature, we chose to limit our searches to empirical data in peer reviewed journals; grey literature 
searches may have identified further information about these services.  Nevertheless, our inclusion 
criteria were broad and identified studies with a diverse range of methodologies.  This proved useful 
in highlighting significant gaps in the available evidence, but limited meaningful comparisons 
between studies.  As a scoping review, the quality of included studies was not evaluated formally.     
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Conclusion 
Recent debate points to uncertainties over the future form of medicine reviews in the UK 73, 74.  It will 
benefit the health of the population if decisions about these and other commissioned pharmacy 
services are informed by high quality evidence.  Despite finding much scope for concern about the 
conduct of MURs and the NMS, evidence from this review indicates also scope for re-alignment of 
MURs and the NMS (or their future iterations) with the core values and skillsets espoused in the 
professional  standards for patient-centred care.  A recent Cochrane review of pharmacy services for 
non-hospitalised patients contained little data directly relevant to this review, and emphasised the 
heterogeneity of data in similar ways to earlier reviews75. It also drew attention to the potential for 
role substitution and anticipated cost savings when health systems broaden the expectations being 
placed on pharmacists. Any sought economic benefits will not be realised, however, unless 
pharmacists are able to help patients manage their own health.  This entails conducting 
consultations with a focus squarely on the needs and goals of the patient, including addressing 
concerns presented and the health outcomes valued by patients, as established from patients’ 
experiences of their medicines and conditions, and what they want from the provision of these 
services.  Simple enquiry and exploration to understand what is important to the individual patient 
are consistent with pharmacist professional values, welcomed by patients, and achievable to deliver 
within existing consultation frameworks.  
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Table 1: Characteristics of RCTs and quasi-experimental studies 
 
  
Study NMS/MUR Objective(s) Design Sample Time 
frame 
Key findings  
Elliott et al. 
2016 
21
  
NMS Examine the effectiveness 
of the NMS on medication 
adherence compared with 
normal practice 
RCT 504 patients 
in 46 
community 
pharmacies 
2012-
2013 
A significantly greater proportion of NMS patients were adherent 
compared to normal practice (71% vs 61%) at 10 week follow-up.  
Adjusted OR for increased adherence was 1.67 in favour of the 
NMS arm.  
Elliott et al. 
2017 
22
 
NMS Examine the effectiveness 
of the NMS on medication 
adherence compared with 
normal practice 
RCT 504 patients 
in 46 
community 
pharmacies 
2012-
2013 
NMS generated a mean of 0.05  more QALYs per patient, at a mean 
reduced cost of -£144 , and a probability of 0.78 [incremental cost-
effectiveness ratio (ICER) -£3166 per QALY] 
Elson et al. 
2017 
24
 
MUR Determine the effects of 
targeted hospital 
pharmacist counselling or 
post-discharge MURs on 
patients' knowledge of 
medication 
Controlled 
(non-
randomised) 
trial 
101 patients 2013 Patients who received pharmacist counselling were more likely to 
report being told the purpose of their new medicine and how to 
take it. Fewer than half of allocated to receive a MUR actually 
received one. 
Ramsbottom 
et al. 2018 
23
 
MUR Evaluate the potential 
clinical and economic 
impact of community 
pharmacists’ 
interventions during post-
hospital discharge MURs 
 
RCT 
feasibility 
study 
20 patients Not 
stated 
An average of 2 interventions were instigated per MUR.  The most 
common was to provide information to improve patient 
understanding of their medication and how to use it in the most 
effective, convenient and safe way.  Indicative cost savings were 
found. 
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Table 2: Characteristics of secondary data analysis studies 
 
  
Study NMS/MUR Objective(s) Design Sample Time 
frame 
Key findings  
Blenkinsopp et 
al. 2008 
25
 
MUR Evaluate the first three 
years of the MUR service 
provision 
Longitudinal 
analysis of 
pharmacy 
MUR 
provision 
records 
1,090 
pharmacies 
2005-
2008 
The number of MURs and pharmacies providing them increased 
over successive years.  Independents were less likely than multiples 
to provide MURs, and those independents that did conducted 
fewer. 
Wells et al. 
2014 
26
 
NMS Investigate the proportion 
of prescription items 
eligible for the NMS and if 
eligibility is affected by 
pharmacies' proximity to 
GP practices 
Cross 
sectional 
analysis of 
prescription 
data 
8005 
prescription 
items 
2013 0.25% of prescription items were eligible for the NMS, lower than 
the assumed 0.5%. The opportunity rate for NMS was 0.21% of 
items, as some eligible items did not translate into opportunities to 
offer the service.  GP proximity made no difference. 
Nazar et al. 
2016 
27
 
NMS/MUR Evaluate an electronic 
patient referral system 
from hospital to 
community pharmacies 
Cross 
sectional 
analysis of 
hospital 
referral data 
2029 patients 2014-
2015 
Only 31% of patients received a community pharmacist follow-up 
consultation.  Most referred patients were over 60 years of and 
referred for a MUR or the NMS. Patients who received a follow-up 
consultation had fewer readmissions and shorter hospital stays. 
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Table 3: Characteristics of mixed methods studies 
Study NMS/MUR Objective(s) Design Sample Time 
frame 
Key findings  
Blenkinsopp et 
al. 2007 
28
 
MUR Measure MUR provision in 
first year of 
implementation 
Postal 
survey; cross 
sectional 
analysis of 
pharmacy 
records; 
interviews 
1,072 
pharmacies; 
29 primary 
care 
organisations 
2005-
2006 
Quantitative: Uptake and spread of MURs was low, and dominated 
by multiples.  
Qualitative: Relationships between pharmacists and GPs a key 
barrier to implementation. 
Bradley et al. 
2008 
29
 
MUR Explore and identify the 
key determinants 
influencing uptake of 
MURs 
Survey, 
interviews 
and cross 
sectional 
analysis of 
MUR data 
MUR data 
from 9872 
pharmacies; 
Survey 
(n=216) of 
primary care 
organisations; 
stakeholder 
interviews 
(n=43) 
2005-
2007 
Quantitative: Rates of MURs by multiples were almost twice that of 
independents.   Survey respondents perceived lack of GP support to 
be the greatest barrier to MUR implementation. 
Qualitative: Organisational pressure within multiple pharmacies was 
identified as driving MUR activity. 
Portlock et al. 
2009 
32
 
MUR Evaluate MUR 
interventions for asthma 
MUR 
outcome 
audit; 
Feedback 
forms 
 
965 patients; 
28 
pharmacists; 
15 GPs 
2007 Quantitative: MUR numbers varied markedly between pharmacies.  
Adherence was greater among patients who had received a GP 
review in the past year.  MURs increased patient knowledge about 
their condition and treatment.   
Qualitative: Patient feedback was positive about overall impression 
of the service, privacy, demonstration of inhalers, explanations of 
medication and convenience. 
15 
 
 
  
Brown et al. 
2014 
31
 
MUR Assess the impact of the 
healthy living pharmacy 
(HLP) framework on 
service provision and staff 
engagement 
Cross 
sectional 
analysis of 
pharmacy 
records; 
interviews 
17 HLPs and 
19 non-HLPs; 
38 community 
pharmacy 
staff, including 
25 
pharmacists 
2011-
2012 
Quantitative: Significantly more clients per pharmacy were seen in 
HLPs than non-HLPs for MURs (medians: 29 vs 11). 
Qualitative: None relevant to MURs. 
Hann et al. 
2017 
30
 
MUR Identify factors associated 
with variation in the 
volume of services 
delivered by community 
pharmacies 
Longitudinal 
analysis of 
national 
MUR data; 
postal 
survey 
10,454 
pharmacies; 
284 pharmacy 
representative
s 
2011-
2016 
Quantitative: Greater volume of MURs was associated with 
pharmacy ownership type (large chains/supermarkets vs 
independents), greater dispensing volume, and lower disease 
prevalence.  Survey responses supported these findings, with MUR 
volume also associated with weekly opening hours and lower 
asthma prevalence. 
 
16 
 
Table 4: Characteristics of surveys 
Study NMS/MUR Objective(s) Design Sample Time 
frame 
Key findings  
Wilcock & 
Harding  2007 
36
  
MUR Explore GPs' perceptions 
of MURs 
Self-
complete 
survey 
52 GPs 2007 GPs reported good relationships with community pharmacists, but 
had negative views about MURs.  Lack of clarity about the purpose 
of MURs and concerns about pharmacists advising on clinical rather 
than practical issues were raised. 
Latif & 
Boardman 
2008 
43
 
MUR Investigate factors that 
influence the number of 
MURs performed by 
community pharmacists 
and pharmacists' attitudes 
towards the service 
Postal 
survey 
167 
community 
pharmacists 
from one 
pharmacy 
chain 
2006 More MURs were performed by store based pharmacists than 
locums, and by those with access to a consultation room.  Most 
respondents felt that MURs would be of benefit to patients, but 
reported concerns about GP opinions of the service, and lack of 
time and support staff to conduct MURs. 
James et al. 
2008 
57
  
MUR Develop criteria for 
assessment of MUR 
referral documentation 
Delphi study 16 Delphi 
panellists 
2006 Twenty MUR quality indicators were agreed. 
Youssef et al. 
2009 
54
 
MUR Evaluate MUR workshops 
for undergraduate 
pharmacy students 
Self-
complete 
survey 
107 
undergraduat
e pharmacy 
students 
Not 
stated 
Students would value demonstration of well and poorly conducted 
MURs, with real life case studies. 
Harding & 
Wilcock  2010 
55
 
MUR Explore existing 
mechanism to ensure 
quality assurance of 
medicine use reviews 
(MURs), and to identify 
those parameters of an 
MUR that community 
pharmacists consider as 
indicators of quality 
 
Postal 
survey 
50 community 
pharmacists 
2008 Pharmacists exercise their judgement about whether to undertake 
a MUR with a patient.  Pharmacists shared a common sense of poor 
practice, but were less clear about defining a well conducted MUR. 
17 
 
Youssef et al. 
2010 
50
 
MUR Examine patient benefit 
following MURs 
Postal 
survey 
81 patients 2008 Two thirds of patients thought they learnt more about their 
medicines after the MUR, 58% thought the MUR increased 
awareness of medicine side effects, and 83% thought the MUR 
improved their compliance.  Older patients perceived more benefit.  
Tucker 2013 
41
 MUR Explore the range of 
dermatology MURs 
undertaken by 
pharmacists and their 
confidence in dealing with 
the provision of advice to 
patients. 
Postal 
survey 
870 
community 
pharmacists 
Not 
stated 
Over 40% of pharmacists undertook dermatology MURs and rated 
themselves as confident in this role.  More MURs were conducted 
by pharmacists employed by multiples. 
Merks et al.  
2016 
45
  
MUR Assess patients’ opinion 
about prevalence of 
pharmaceutical services 
available in a community 
pharmacy in a rural area 
and identify appropriate 
action(s) to enhance 
patients’ awareness of 
pharmaceutical services in 
rural areas. 
Self-
complete 
Survey 
103 patients 2015 Awareness of expanded pharmaceutical services was poor; MUR 
was the only advanced service used (by 13% of respondents), 
primarily by men. 
Rodgers et al. 
2016 
48
 
NMS/MUR Compare the perceptions 
of pharmacists and the 
general public on MURs 
and the NMS. 
Street and 
postal 
surveys 
1000 public 
respondents; 
341 
pharmacists 
2012 Few from the public sample were aware of MURs or the NMS.  
Pharmacists estimated spending 10 minutes on MURs and 12 
minutes on NMS; acceptable to both pharmacists and the public. 
Expectations of services increasing knowledge and understanding 
of medication were high, but did reflect public experiences of the 
services.  
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Twigg et al. 
2016 
64
 
MUR Examine information 
needs and reported 
adherence of patients 
who received a 
community pharmacy 
advanced service. 
Postal 
survey 
232 patients 
from 4 
community 
pharmacies 
Not 
stated 
All respondents desired further information about their prescribed 
medicines, particularly about potential medication problems. 
Satisfaction with information about medicines and adherence were 
significantly greater among patients who had received an advanced 
service, such as a MUR. 
Cheema et al. 
2017 
60
 
NMS Assess the impact of the 
NMS on medication use 
by patients starting a new 
medication for a long-
term medical condition. 
Pharmacist 
completed 
questionnair
es  
285 patients 2012 On the first NMS assessment, 82 patients reported drug-related 
problems of whom 58 received pharmacists' advice. At follow up 39 
(67%) of these 58 patients reported resolution of problems 
compared to 17% of the patients who did not receive pharmacists' 
advice (OR=10.2). 
Hamedi et al.  
2017 
58
 
NMS Assess community 
pharmacists' practice, 
knowledge and 
confidence in supporting 
patients' adherence as 
part of the NMS for 
patients on Oral Anti-
Coagulants for stroke 
prevention in Atrial 
Fibrillation 
On-line 
survey 
257 patients
  
2014-
2015 
Priorities during the NMS consultation were to discuss actions to 
take when bleeding occurs and supporting adherence. Pharmacists 
were more confident in their knowledge, skills and access to 
resources for Vitamin-K Antagonists than for new oral 
anticoagulants. 
Hindi et al. 
2017 
49
 
MUR Develop, pilot, and utilize 
a MUR patient satisfaction 
questionnaire 
Postal 
survey 
505 patients 2016 Patients showed a high degree of overall satisfaction with MURs, 
even if initially reluctant to take part in one.  
19 
 
 
 
  
Rutter et al. 
2017 
44
 
MUR Investigate the 
perspective of community 
pharmacists on the 
usefulness of and 
suitability of MUR 
referrals from hospital. 
Postal 
survey 
19 community 
pharmacists 
Not 
stated 
Barriers to implementation were failure or inability of patients to 
attend the pharmacy.  Community pharmacists' views of the 
service were positive, but felt further medications information 
would be useful for referrals. 
Aston et al 
2018  
46
 
NMS/MUR Determine whether 
community pharmacists 
undertake MUR or NMS 
with children/their carers 
and identify the type of 
medication-related 
experiences presented to 
them when a child is 
taking long-term 
medication 
Postal 
survey 
76 community 
pharmacists 
2015 MUR and NMS utilised by community pharmacists for 
children/carers.  Presentations were for non-adherence including 
stopping medication and changing dose. Pharmacists were directly 
asked about dose, administration and adverse effects.  
20 
 
Table 5: Characteristics of qualitative studies 
Study NMS/MUR Objective(s) Design Sample Time 
frame 
Key findings  
Urban et al. 
2008 
39
 
MUR Explore community 
pharmacists' 
experience of 
conducting MJRs 
Interviews 21 community 
pharmacists 
Not 
stated 
Uncertainty about the best ways to select and recruit patients for 
MURs.  Perception that MURs improve patient understanding and use 
of their medications.  Perception that GPs have doubts about the 
value of MURs. 
McDonald et 
al. 2010 
42
 
MUR Explore community 
pharmacists' 
reactions to the 
introduction of 
MURs 
Interviews 49 community 
pharmacists 
2007-
2008 
Support for MURs was high, although workload pressures hindered 
pharmacists ability to undertaken them.  Some pharmacists (from 
multiples) felt under pressure to meet MUR targets. 
van den Berg 
M & Donyai 
2010 
53
 
MUR Investigate the 
depiction of the 
patient–pharmacist 
power relationship 
within MUR patient 
information leaflets 
 
Discourse 
analysis 
11 leaflets 2006 A variety of terminology was used to describe MURs, with the 
intended cooperative nature of the service not fully described.   
Latif et al. 
2011 
17
 
MUR Understand the 
contribution of 
MURs to 
counselling practice 
Observations, 
patient and 
pharmacy staff 
interviews 
54 MURs,  34 
patient 
interviews, 17 
staff interviews, 
from 2 
community 
pharmacies 
2008-
2009 
MURs were short, with pharmacists asking mainly closed questions.  
Patients rarely asked questions. Knowledge and use of medicines was 
largely unaffected.  Practical factors hindered MUR implementation. 
21 
 
Latif et al. 
2013 
33
  
MUR Examine patient 
perspectives  of 
MURs and GP-
pharmacist 
collaboration 
Observations 
and interviews 
54 MURs, 34 
patient 
interviews, 17 
staff interviews, 
from 2 
community 
pharmacies 
2008-
2009 
Patients reported positive views about MURs.  Little evidence of 
pharmacists and GPs working collaboratively. MURs conducted in 
isolation from other aspects of patient care. Potential for MURs to 
cause tensions with GPs.  
Latif et al. 
2013 
34
 
MUR Describe patients' 
perspective of the 
MUR service and 
what value that 
they derive from it. 
Observations 
and interviews 
34 patients from 
2 community 
pharmacies 
2008-
2009 
Patients were comfortable speaking with the pharmacist and the 
MUR provided reassurance about their medicines.  The purpose of 
MURs was unclear to patients and did not improve their medicine 
knowledge or use. 
Latif et al. 
2013 
35
 
MUR Explore the impact 
and consequences 
of MURs on 
pharmacy support-
staff 
Observations 
and interviews 
5 community 
pharmacists; 12 
support staff 
2008-
2009 
Some support-staff felt frustrated when left to explain to patients 
why the pharmacist was not available when carrying out an MUR.   
van den Berg 
M & Donyai 
2014 
51
 
MUR Develop a patient 
satisfaction 
conceptual 
framework  
Observations 
and  interviews 
7 MURs and 15 
patient 
interviews 
2008-
2010 
Five themes identified: relationships with healthcare providers; 
attitudes towards healthcare providers; patients' experience of 
health, healthcare and medicines; patients' views of the MUR service; 
the logistics of the MUR service.  
22 
 
Wells et al. 
2014
40
  
NMS Explore 
pharmacists' views 
and experiences of 
the NMS prior to 
implementation to 
identify facilitators 
and barriers to its 
success 
Focus groups 
and interviews 
15 community 
pharmacists; 5 
superintendent 
pharmacists 
2011 Views of the NMS were positive.  Potential barriers included lack of 
interest/awareness by GPs and the payment structure, speed of 
implementation, and absence of some support materials. 
Lucas & 
Blenkinsopp 
2015 
38
 
NMS Explore community 
pharmacists' 
experiences and 
perceptions of NMS 
Interviews 14 community 
pharmacists 
2012 Pharmacists perceived the NMS as beneficial, providing additional 
advice and reassurance to patients.  The opportunity to utilise their 
professional expertise was welcomed, but different levels of 
collaborative working with GPs were reported. 
Latif et al. 
2016 
37
 
NMS Explore NMS 
implementation  
Observations 
and interviews 
47 community 
pharmacists and 
11 GPs 
2012-
2013 
Pharmacists were pragmatic, simplifying, and adapting the NMS to 
facilitate delivery. Pharmacists held positive views about the value of 
the NMS, but reported not identifying problems with medicines.  
Poor pharmacist-GP relationships impeded implementation. 
Waring et al. 
2016 
59
 
NMS Explore changing 
dynamics of 
pharmacist-patient 
power after 
introduction of the 
NMS 
Observations 
and interviews 
20 patients and 
27 community 
pharmacists 
2012-
2013 
NMS extends the ‘pharmacy gaze’ to further aspects of patients' 
health and lifestyle, beyond dispensing and advice giving, and results 
in greater complexity in pharmacist-patient relational power.   
23 
 
 
Latif et al. 
2018  
47
 
MUR Explore the 
medicine needs of 
patients from 
marginalised 
communities and 
how services could 
better meet their 
requirements 
Workshops and 
interviews 
Workshops: 23 
patients; 24 
pharmacy 
professionals 
Interviews: 10 
patients; 10 
pharmacy staff 
2016 Patients reported poor management of their conditions and 
problems with adherence. Experiences of pharmacy services were 
variable, with many experiencing discrimination or disadvantage. 
Latif et al. 
2018 
52
 
NMS Examine 
implementation of 
the NMS 
Observation 
and interviews 
Observation: 20 
patients 
Interviews: 35 
patients; 47  
community 
pharmacists; 11 
GPs 
2012-
2013 
Patients were generally unaware of the NMS.  Patients tended to 
report having no problems with their medicines or to adopt their own 
strategies for dealing with them.  Consultations were generally 
passive and focussed on how patients were 'getting on' with their 
medication. 
24 
 
Figure 1: PRISMA flow chart of search strategy and article selection 
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Additional records identified from 
hand searches  
(n = 6) 
Records after duplicates removed 
(n = 141) 
Records screened 
(n =141) 
Records excluded 
(n =95) 
Full-text articles assessed 
for eligibility 
(n = 46) 
Full-text articles excluded, with 
reasons (n = 5) 
 
-No empirical data (n = 3) 
-Not MUR or NMS (n = 1) 
-Feasibility study (n = 1) 
 
Articles included in 
synthesis 
(n = 41) 
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